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Perlecan-Induced Suppression of Smooth Muscle Cell
Proliferation Is Mediated Through Increased Activity of the
Tumor Suppressor PTEN
Pamela J. Garl, Janet M. Wenzlau, Heather A. Walker, John M. Whitelock,
Mercedes Costell, Mary C.M. Weiser-Evans
Abstract—We were interested in the elucidation of the interaction between the heparan sulfate proteoglycan, perlecan, and
PTEN in the regulation of vascular smooth muscle cell (SMC) growth. We verified serum-stimulated DNA synthesis, and Akt
and FAK phosphorylation were significantly reduced in SMCs overexpressing wild-type PTEN. Our previous studies showed
perlecan is a potent inhibitor of serum-stimulated SMC growth. We report in the present study, compared with SMCs plated
on fibronectin, serum-stimulated SMCs plated on perlecan exhibited increased PTEN activity, decreased FAK and Akt
activities, and high levels of p27, consistent with SMC growth arrest. Adenoviral-mediated overexpression of constitutively
active Akt reversed perlecan-induced SMC growth arrest while morpholino antisense-mediated loss of endogenous PTEN
resulted in increased growth and phosphorylation of FAK and Akt of SMCs on perlecan. Immunohistochemical and Western
analyses of balloon-injured rat carotid artery tissues showed a transient increase in phosphoPTEN (inactive) after injury,
correlating to high rates of neointimal cell replication; phosphoPTEN was largely limited to actively replicating SMCs.
Similarly, in the developing rat aorta, we found increased PTEN activity associated with increased perlecan deposition and
decreased SMC replication rates. However, significantly decreased PTEN activity was detected in aortas of perlecan-deficient
mouse embryos, consistent with SMC hyperplasia observed in these animals, compared with E17.5 heterozygous controls that
produce abundant amounts of perlecan at this developmental time point. Our data show PTEN is a potent endogenously
produced inhibitor of SMC growth and increased PTEN activity mediates perlecan-induced suppression of SMC proliferation.
(Circ Res. 2004;94:175-183.)
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Vascular smooth muscle cells (SMCs) demonstrate highrates of replication during embryonic development signif-
icantly contributing to the maturation of the vessel wall.1 In
addition, SMCs are capable of marked increases in replication
after injury to the mature vessel wall, a major component of the
vessel remodeling observed in a variety of vascular patholo-
gies.2,3 In the absence of vascular trauma, the mature blood
vessel remains a highly quiescent tissue and SMCs are resistant
to stimulation by most mitogens,2–5 suggesting the existence of
active growth-suppressive mechanisms. SMCs in mature arteries
are surrounded by a basement membrane matrix.6 Our previous
studies showed the accumulation of a perlecan-rich basement
membrane actively inhibits SMC growth.7–10
Perlecan, a large multidomain heparan sulfate proteoglycan, is
essential for the assembly and maintenance of a functional
basement membrane.11–14 Homozygous perlecan-null mice die
in utero and, important to our studies, display hyperplasia of
SMC-specific -actin–positive mesenchymal cells.13–15 We
showed perlecan expression is initiated in early fetal life when
the first postreplicative SMCs appear and expression is limited
to nonreplicating SMCs.7,9 Decreased SMC-derived perlecan
production is associated with increased SMC replication rates
after vascular injury.16 However, accumulation of perlecan in the
later stages of injury repair is associated with the attenuation of
neointimal SMC proliferation. Our recent studies show perlecan-
induced SMC growth suppression is mediated, at least in part,
through the active upregulation of focal adhesion kinase-related
nonkinase (FRNK), which subsequently suppresses FAK-
dependent growth signals.10 In the present study, we sought to
identify factors downstream of perlecan capable of mediating
these molecular events.
PTEN, first discovered as a potent tumor suppressor, is a
dual-specificity lipid and protein phosphatase17–20 and a
negative regulator of PI3K- and FAK-mediated signaling.
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PTEN directly antagonizes growth factor receptor– and integrin-
stimulated signaling, thus promoting cell cycle arrest, decreased
cell migration, and apoptosis. Compared with its role in cancer
biology, there is a smaller, but growing accumulation of data
regarding PTEN’s role in normal physiological processes.
PTEN-null mice die between E6.5 and E9 and exhibit poorly
organized ectodermal and mesodermal layers, demonstrating
PTEN’s importance in embryonic development.21,22 However,
little is known still about upstream regulators of PTEN phos-
phatase activity or its role in vascular SMC biology. Our
previous work demonstrated high in vivo SMC growth rates
during vascular development and after vascular injury are
associated with decreased perlecan expression and PTEN inac-
tivation.23 In the present study, we hypothesized perlecan:SMC
interactions upregulate PTEN phosphatase activity mediating
perlecan-induced SMC growth suppression.
Materials and Methods
An expanded Materials and Methods section can be found in the
online data supplement available at http://www.circresaha.org.
Results
PTEN Overexpression Inhibits SMC Growth and
Activation of Akt and FAK
To verify PTEN inhibits SMC growth and Akt and FAK
activities, SMCs were transiently transfected with a CMV
promoter-based vector encoding wild-type GFP-tagged
PTEN or phosphatase-dead GFP-tagged mutant PTEN.
Transfected SMCs were replated on fibronectin-coated cov-
erslips in the presence of 10% CS and bromodeoxyuridine
(BrdU) for 24 hours. SMCs were immunofluorescently
stained for BrdU, and the percentage of BrdU-positive,
GFP-positive SMCs was determined. SMCs transfected with
vector alone or with the mutant PTEN construct demonstrated
high rates of DNA synthesis in response to serum stimulation
(Figure 1A). In contrast and consistent with a previous
study,24 DNA synthesis was significantly decreased in SMCs
overexpressing wild-type PTEN suggesting PTEN is a very
potent inhibitor of SMC growth.
Figure 1. PTEN overexpression inhibits
SMC growth and Akt and FAK phos-
phorylation. A, Left, A10 rat aortic SMCs
were transfected with wild-type GFP-
tagged PTEN, dominant-negative,
phosphatase-inactive GFP-tagged
PTENC124A, or an empty GFP plasmid,
allowed to recover for 24 hours, then
replated on coverslips precoated with
fibronectin in the presence of 10% CS
and 10 mmol/L BrdU. Cells were fixed
24 hours later and immunofluorescently
stained for BrdU and DAPI. The percent-
age of BrdU-positive cells was deter-
mined independently for nontransfected
and transfected SMCs by counting a
minimum of 200 SMCs per condition.
The data are presented as the
meanSE. *P0.05, different than non-
transfected SMCs. Top panel shows a
representative immunofluorescent stain.
Arrowheads indicate GFP-positive SMCs.
Red nuclei indicate BrdU-positive SMCs.
Right, Cell lysates were collected from
parallel cultures and analyzed by West-
ern analysis for GFP expression to verify
transfection. B, A10 SMCs transfected
as above were replated on fibronectin-
coated coverslips for 4 hours. SMCs
were fixed and immunofluorescently
stained for phosphoFAK (top panels) or
phosphoAkt (bottom panels) using phos-
phospecific antibodies. Arrowheads indi-
cate GFP-positive SMCs.
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PTEN antagonizes Akt- and FAK-mediated signaling, and
we showed FAK phosphorylation is essential for SMC
replication.10 SMC cultures transfected as above were fixed
for immunofluorescent analysis of activated Akt and FAK
using phosphospecific antibodies. Nontransfected SMCs and
mutant PTEN-transfected SMCs exhibited high levels of
phosphoAkt and phosphoFAK (Figure 1B). In contrast, al-
though PTEN wild-type overexpressing SMCs attached on
fibronectin (FN), there was little, if any phosphoAkt and
phosphoFAK present.
Perlecan Heparan Sulfate:SMC Interactions
Increase Endogenous PTEN Activity
As shown above, PTEN overexpression suppresses SMC pro-
liferation likely, as with other cell systems, due to swamping a
normally fine-tuned signaling system. PTEN is a protein phos-
phatase whose activity is decreased by phosphorylation25,26;
however, little is known of endogenous upstream regulators of
PTEN phosphorylation. Recent data from other cell systems
suggest PTEN dephosphorylation, and a subsequent increase in
activity is the regulated event.25,26 We demonstrated perlecan
heparan sulfate:SMC interactions result in sustained inactivation
of FAK activity and inhibition of serum-stimulated SMC
growth.10 We next examined the ability of perlecan and
perlecan-rich basement membranes and growth inhibitory ma-
trices to increase endogenous PTEN activity in cultured SMCs.
SMCs were plated in the presence of 10% CS on intact basement
membranes or on individual matrices of perlecan or fibronectin
(a growth-promoting matrix) for 24 hours. Equal amounts of
total PTEN, FAK, and Akt proteins were expressed under all
conditions (Figure 2A). Very low levels of phosphoPTEN were
detected in SMCs plated on perlecan or basement membranes
(Figures 2A and 2B). In contrast, abundant phosphoPTEN was
detected in SMCs plated on fibronectin. Phosphorylation of
FAK and Akt was suppressed in SMCs plated on perlecan and
intact basement membranes, compared with SMCs plated on
fibronectin (Figures 2A and 2B). In addition, SMCs plated on
growth inhibitory matrices exhibited increased p27 levels (Fig-
ures 2A and 2B), a protein previously shown to be upregulated
by PTEN.27 These data are consistent with the low growth
potential of SMCs on these matrices, despite the addition of
serum (Figure 2C).
To examine the role of glycosaminoglycan chains in
mediating perlecan’s effect on PTEN, intact basement mem-
branes were treated with heparinase I/II, chondroitinase ABC,
or hyaluronidase. SMCs were then plated on untreated or
digested membranes in the presence of 10% CS. In contrast to
untreated, chondroitinase-, or hyaluronidase-treated mem-
branes, SMCs plated on heparinase-treated basement mem-
branes exhibited higher levels of phosphoPTEN (Figure 3A),
suggesting heparan sulfate side chains contribute to perlecan-
induced upregulation of PTEN activity. The increase in
phosphoPTEN, however, was considerably less than ob-
served in SMCs plated on fibronectin (Figure 3A).
Since loss of heparan sulfate moieties in part decreased PTEN
activity, we examined the effect of exogenous heparin in
regulating PTEN under standard culture conditions. SMCs were
cultured on tissue culture plastic, growth-arrested in serum-free
conditions, and then stimulated with various growth factors and
inhibitors. Equal amounts of total PTEN protein were expressed
under all conditions (Figure 3B). SMCs plated on plastic
exhibited high levels of phosphoPTEN in serum-free medium
and after serum, PDGF, FGF2, EGF, IGF1, or TGF1 stimula-
tion (Figure 3B). We found decreased phosphorylation (ie,
increased activity) only after incubation of serum-deprived
SMCs with exogenous heparin.
Akt Activation Reverses Perlecan-Mediated SMC
Growth Suppression
Our previous work showed growth inhibition by perlecan is
partially reversed by overexpressing constitutively active
FAK.10 Therefore, we determined whether overexpression of
constitutively active Akt could also reverse perlecan-induced
SMC growth inhibition. SMCs were transduced with a
replication-defective adenovirus expressing either GFP (pAd-
GFP) or an active form of Akt (pAd-MyrAkt) and replated in
Figure 2. Perlecan:SMC interactions
increase endogenous PTEN activity. A
and B, Rat aortic SMCs were growth-
arrested for 72 hours in serum-free
medium and replated in the presence of
10% CS on basement membranes (BM)
or on culture dishes precoated with per-
lecan (PN) or fibronectin (FN). Whole-cell
lysates were prepared 24 hours after
replating and analyzed by Western analy-
sis for the indicated proteins. Western
analyses from 3 independent experi-
ments were scored for relative densitom-
etry (phosphoproteins normalized to total
proteins; p27 to -actin); the data are
presented in the graph. *P0.05, differ-
ent than FN. C, Rat aortic SMCs were
cultured on precoated dishes as above
in the presence of 10 mmol/L BrdU.
Cells were fixed 24 hours later and
immunofluorescently stained for BrdU
and DAPI. Arrowheads indicate BrdU-
positive SMCs on PN; arrow, BrdU-
negative SMCs on FN.
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the presence of 10% CS on basement membranes, fibronec-
tin, or tissue culture plastic for 4 days (Figure 4). Compared
with SMCs plated on fibronectin or plastic, GFP-transduced
SMCs plated on basement membranes showed no increase in
cell number in response to serum stimulation. In contrast,
MyrAkt-transduced SMCs exhibited significant increases in
cell number in response to serum stimulation even when
plated on basement membranes, suggesting Akt inactivation
is a significant factor in perlecan-mediated SMC growth
suppression. Western analysis confirmed pAd-MyrAkt–trans-
duced SMCs exhibited increased phosphoAkt even when
plated on basement membranes (Figure 4).
Morpholino-Mediated Inhibition of PTEN
Increases Growth and Akt and FAK Activation of
SMCs Plated on Perlecan
To determine if the SMC growth inhibitory effects of perle-
can are mediated through PTEN, SMCs were transfected with
PTEN antisense morpholino oligonucleotides to reduce en-
dogenous PTEN. Inverse antisense morpholino oligonucleo-
tides were used as controls. SMCs were replated on perlecan
or fibronectin matrices in the presence of 10% CS and BrdU
for 24 hours. Antisense treatment resulted in a significant loss
of endogenous PTEN protein compared with inverse
antisense-treated or untreated controls (Figure 5B). Consis-
tent with our previous studies, untreated and inverse
antisense-treated SMCs demonstrated low growth rates when
plated on perlecan. In contrast, PTEN antisense treatment
resulted in significant increases in SMC replication on per-
lecan with growth rates comparable to those observed in
SMCs plated on fibronectin (Figure 5A). Loss of endogenous
PTEN resulted in increased phosphorylation of Akt and FAK
in SMCs plated on perlecan (Figure 5B). Our previous studies
showed perlecan-induced upregulation of FRNK contributes
to SMC growth inhibition.10 Morpholino-mediated loss of
endogenous PTEN also resulted in decreased FRNK levels in
SMCs plated on perlecan (Figure 5B), implying the presence
of PTEN-responsive regulatory elements in the FRNK pro-
moter. Ongoing studies in our laboratory are exploring this
possibility. Our data strongly suggest perlecan is an upstream
regulator of endogenous PTEN activity and increased PTEN
activity inhibits SMC proliferation through the downregula-
tion of FAK- and Akt-dependent signaling.
High Levels of PhosphoPTEN Correlate to High
In Vivo SMC Growth Rates, and PTEN Activity
in the Developing Aorta Is Decreased in E17.5
Perlecan-Deficient Embryos
Our previous work showed increased levels of phosphoPTEN
are observed in 7-day postinjured compared with sham-
injured carotid artery tissues consistent with increased growth
rates at this time.23 Immunohistochemistry was used on a
series of sham- and balloon-injured carotid arterial tissues to
determine the temporal and spatial pattern of expression of
phosphoPTEN (Figure 6A). Abundant levels of total PTEN
protein were detected in the arterial media of sham and
injured vessels and significantly elevated levels were found in
the growing neointima. In contrast, very little phosphoPTEN
was detected in sham-injured vessels corresponding to low
SMC growth rates. However, at 2 days after injury, elevated
phosphoPTEN was detected in medial SMCs, particularly in
cells nearest the vessel lumen. By 4 to 10 days after injury,
abundant phosphoPTEN was detected predominantly in the
neointima. Fourteen days after injury, expression of phos-
phoPTEN was greatly diminished and was virtually undetect-
able by 28 days after injury. Western analysis of vessel
protein expressions confirmed the immunohistochemistry
data (Figure 6B).
Since the pattern of phosphoPTEN correlated to high rates
of SMC replication and, in particular, neointimal SMC
replication, we examined the relationship between SMC
replication and phosphoPTEN expression on a cell-to-cell
Figure 3. Perlecan heparan sulfate chains and exogenous hepa-
rin upregulate PTEN activity. A, Basement membranes (BM)
were digested with 10 U/mL heparinase I/II (H’ase), 1 U/mL
chondroitinase ABC (C’ase), or 0.1% hyaluronidase (Hyal’ase)
for 4 hours at 37°C. Rat aortic SMCs were plated on untreated
or treated membranes or on fibronectin (FN) in the presence of
10% CS. Cell lysates were prepared after 24 hours, and equal
protein concentrations were analyzed by Western analysis for
phosphoPTEN or total PTEN. Western analyses from 3 indepen-
dent experiments were scored for relative densitometry, and the
data are presented in the graph (phosphoPTEN normalized to
total PTEN). *P0.05, different than basement membrane. B,
Rat aortic SMCs were plated on tissue culture plastic, growth-
arrested for 48 hours in serum-free DMEM, then stimulated with
the indicated factors. Cell lysates were prepared after 24 hours,
and equal protein concentrations were analyzed by Western
blotting as described in A.
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basis. Using a double-labeling PCNA-phosphoPTEN immu-
nohistochemistry technique, we simultaneously determined
DNA synthesis and phosphoPTEN expression in a single
SMC in day 7 and day 10 postinjured carotid arteries. High
levels of phosphoPTEN were expressed almost exclusively
by replicating cells (PCNA-positive) of the neointima (Figure
6C). Collectively, these data suggest high rates of SMC
replication after vascular injury are associated with PTEN
inactivation. In addition, the observed expression pattern of
phosphoPTEN after vascular injury correlates inversely to
that reported for perlecan.15
The above data demonstrate the in vivo pattern of active
PTEN expression is similar to the pattern of perlecan mRNA
and protein expression and inversely correlated with the
degree of SMC replication observed after vascular injury.
Similarly, we demonstrated the temporal expression of per-
lecan during vascular development is directly related to SMC
quiescence.7 We therefore determined the relationship be-
tween endogenous perlecan expression and PTEN activity in
the developing aorta by first examining a developmental
series of rat aortic tissues for the pattern of phosphoPTEN
expression (Figure 7A). High levels of phosphoPTEN were
detected in E15 and E16 aortas corresponding to a period of
rapid SMC replication. Loss of phosphoPTEN expression
was observed at E19 and remained undetectable at E21. The
temporally regulated increase in PTEN activity correlates
with increased deposition of perlecan and occurs at a period
when rat aortic SMC replication significantly declines.
Since the developmental patterns of active PTEN and
perlecan are similar, we examined the expression pattern of
phosphoPTEN in the developing aorta of perlecan-null mouse
embryos. E17.5 heterozygous controls produce abundant
amounts of perlecan at this developmental time point (com-
parable time when rat aortic perlecan deposition is high)
(Figure 7C) and phosphoPTEN was virtually undetectable
(Figure 7B). In contrast, PTEN activity was significantly
decreased (increased phosphorylation) in aortas of age-
matched perlecan-deficient embryos, consistent with SMC
hyperplasia observed in these animals (Figure 7B). Collec-
tively the present data suggest PTEN is less active in
developing SMCs, contributing to a highly proliferative
phenotype. At distinct times during the developmental pro-
cess, increases in perlecan production induce an upregulation
of PTEN activity thus contributing to SMC quiescence.
Figure 4. Constitutively active Akt
reverses perlecan-mediated SMC growth
suppression. Rat aortic SMCs were trans-
duced overnight with pAd-GFP or pAd-
Myr-Akt (MOI100), allowed to recover for
24 hours, then plated on basement mem-
branes, fibronectin, or tissue culture plastic
in the presence of 10% CS. Total cell
numbers were determined in triplicate after
4 days of serum stimulation. The data are
presented as the meanSE of 3 indepen-
dent experiments. *P0.05, different than
pAd-GFP–transduced SMCs plated on
basement membranes. B, Whole-cell
lysates were collected from SMC cultures
treated as described in A and analyzed for
phospho- and total Akt, HA (for transduc-
tion efficiency), and -actin (control for
protein loading) using specific antibodies.
Figure 5. Antisense-mediated reduction of
PTEN increases SMC growth on perlecan.
A10 rat aortic SMCs were transfected with
FITC-labeled PTEN-specific morpholino
antisense or inverse antisense oligonucleo-
tides and allowed to recover for 30 hours.
Control SMCs were treated with morpho-
lino delivery solution only. A, Transfected
SMCs were replated on coverslips pre-
coated with perlecan (black bars) or
fibronectin (gray bars) in the presence of
10% CS and 10 mmol/L BrdU. Cells were
fixed 24 hours later and immunocyto-
chemically stained for BrdU (red nuclei).
The data are presented as the meanSE.
Top panel shows a representative immu-
nofluorescent stain of transfected SMCs
plated on PN (antisense, left panel; inverse
antisense, middle panel) or FN (antisense,
right panel). B, Cell lysates were prepared
from transfected SMCs plated on PN as
described above and analyzed by Western
analysis for total PTEN, phosphoAkt, phos-
phoFAK, FRNK, and -actin (control for
protein loading).
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Discussion
During vascular morphogenesis, SMCs undergo a phase of
rapid proliferation, during which time the vessel wall acquires
its complement of SMCs.1 Replication significantly decreases
as the vessel matures, and SMCs remain highly quiescent in
the mature, uninjured artery. The ability of these cells to
rapidly, but transiently, proliferate after vascular injury sug-
gests active inhibitory and stimulatory mechanisms coordi-
nately regulate SMC growth.2,3 Mechanisms of endogenous
SMC growth inhibition are poorly understood. Previous
studies from our laboratory have shown timed accumulations
of perlecan heparan sulfate into the SMC basement mem-
brane contributes to SMC growth suppression at least in part
via the upregulation of FRNK, which subsequently down-
regulates FAK-mediated growth signals.7,10 In this study, we
extend these findings and report perlecan:SMC interactions
increase PTEN activity, mediating perlecan-induced SMC
growth arrest via decreased FAK and Akt signaling despite
serum stimulation. Morpholino antisense-mediated reduction
of endogenous PTEN reversed growth and Akt and FAK
activities of SMCs plated on perlecan. In addition, we report
increases in PTEN activity directly correlate to perlecan
deposition and inversely correlate to SMC replication during
vascular development and after vascular injury. Accordingly,
in the developing aorta of perlecan-null mice, we found
decreased PTEN activity associated with SMC hyperplasia.
The central finding of this study is SMC quiescence is
actively controlled through temporally regulated increases in
activity of the growth suppressor PTEN via upregulation of
SMC-derived perlecan expression. Perlecan expression and
PTEN activity are associated with developmental and late
postinjury decreases in SMC replication.7,16 PTEN inactiva-
tion is associated specifically with actively dividing SMCs
during early to mid stages of lesion formation. In the early
stages of injury repair, SMCs proliferate in response to
increased release of growth factors.28,29 In addition, vascular
injury is associated with upregulation of several proteolytic
and glycolytic enzymes, contributing to basement membrane
and extracellular matrix (ECM) degradation and remodel-
ing.30,31 Degradation of inhibitory matrix proteins, such as
Figure 6. PTEN activity is inversely correlated to SMC replication after vascular injury. A, Immunohistochemistry was used to analyze
total PTEN (lower photomicrographs) and phosphoPTEN (upper photomicrographs) expression in rat carotid artery tissue sections from
sham- or balloon-injured arteries (2, 4, 7, 10, 14, and 28 days after injury); the reaction color is reddish-brown. Serial sections from
each time point were stained. The arterial lumen is oriented toward the top of each panel. Arrowheads mark the internal elastic lamina.
B, Arteries as described above were harvested at the indicated times, stripped of adventitia, and equal protein concentrations from
whole-cell lysates were analyzed by Western analysis for phosphoPTEN (P-PTEN), total PTEN, and -actin (control for protein loading).
Western analyses from 3 independent experiments were scored for relative densitometry, and the data are presented in the graph
(phosphoPTEN normalized to total PTEN). *P0.05, different than sham-injured. C, Sections of 7-day (left panel) and 10-day (right
panel) injured carotid arteries were examined by double-labeling immunohistochemistry for expression of phosphoPTEN concurrently
with PCNA to detect replicating SMCs. Brown nuclei indicates PCNA-positive SMCs; blue reaction color, phosphoPTEN. Arrowheads
indicate the internal elastic lamina; arrows, representative PCNA-positive SMCs expressing significant levels of phosphoPTEN.
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perlecan, and increased deposition of growth stimulatory
matrix proteins, such as fibronectin, are observed at these
stages. Our data show SMC interactions with perlecan in-
crease PTEN activity and block mitogen-stimulated SMC
proliferation, suggesting the induction of SMC proliferation
after injury requires a balance between loss of active growth
inhibitory signals and gain of active growth stimulatory
signals.
While medial SMCs proliferate in response to growth
factors, such as PDGF and bFGF, in the early stage after
vascular injury, the mechanisms regulating continual cell
replication during intimal thickening appear to be growth
factor–independent.28,29 We and others have shown transient
increases in Akt activity associated with peak intimal cell
replication.23,32 In addition, we reported neointimal SMCs
transiently express a unique, highly proliferative phenotype
characteristic of embryonic SMCs rather than traditional
adult-derived vascular SMCs.3,23,33 This phenotype is associ-
ated with growth factor–independent cell replication, low
perlecan expression, PTEN inactivation, and constitutive Akt
signaling. Elevated levels of phosphatidylinositol 3,4,5-
trisphosphate, the predominant PTEN substrate, are observed
in PTEN-deficient cells and are sufficient to activate Akt to
transduce proliferative signals in the absence of other stimu-
li.19,20 Morpholino-mediated knockdown of endogenous
PTEN not only reverses SMC growth inhibition by perlecan
but also induces a mitogen-independent, embryonic-like phe-
notype.23 Likewise, inhibition of perlecan increases serum-
stimulated10 and mitogen-independent (M.C.M.W.-E.; un-
published results, 2003) growth of adult-derived SMCs. We
therefore propose rapid intimal cell growth during neointimal
formation is driven, in large part, via loss of perlecan-
mediated PTEN activation resulting in constitutive Akt sig-
naling. Constitutive FAK signaling may likewise contribute
to rapid SMC growth due to decreased perlecan-induced
FRNK expression.10
The molecular mechanism mediating perlecan’s effect on
PTEN remains undefined. The present data and our previous
work8,10 indicate at least some of the growth inhibitory
activity of perlecan resides in its highly sulfated HS chains,
consistent with a large body of evidence implicating heparin-
like molecules in the regulation of SMC growth.34–38 In this
respect, HS chains of perlecan may bind heparin-binding
growth factors, thus attenuating growth factor–mediated
SMC replication. In agreement, a previous study showed
proliferative responses to growth factors of intimal SMCs in
late lesions is increased after heparinase treatment.16 Addi-
tionally, heparin increases SMC-derived perlecan core pro-
tein production, which may, in turn, promote SMC growth
inhibition.7 However, we have consistently shown heparin or
HS chains alone do not elicit the same degree of growth
inhibition as fully sulfated perlecan, especially under serum-
stimulated conditions. This suggests the efficacy of perlecan
on SMC growth inhibition may derive from the coordinate
actions of perlecan HS chains and binding of the core protein
to the SMC surface.
In addition, interaction of perlecan with various ECM
proteins, including collagens, fibronectin, and laminin,39
could interfere with ECM-integrin interactions that otherwise
facilitate growth factor–stimulated SMC replication. The
present results show SMC adhesion to fibronectin results in
robust phosphorylation, and therefore inactivation, of PTEN
associated with increased integrin- and growth factor–medi-
ated signaling events supporting this hypothesis. In addition,
Lundmark et al40 demonstrated a combined matrix of perle-
can and fibronectin inhibits SMC adhesion to fibronectin. In
this scenario, perlecan could passively activate PTEN by
blocking growth factor receptor– and/or integrin-induced
phosphorylation of PTEN.
Figure 7. PTEN activity in the developing
aorta is decreased in E17.5 perlecan-
deficient embryos. A, Immunohistochem-
istry was used to localize phosphoPTEN
(upper photomicrographs) and total
PTEN protein (lower photomicrographs)
in the aortas of E15, E16, E19, and E21
rat embryos; the reaction color is
reddish-brown. Serial sections were
stained. The arterial lumen is oriented
toward the top of each panel. B, E17.5
perlecan heterozygous (PN /) and
homozygous mutant (PN /) embryos
were harvested, fixed, and processed for
immunohistochemistry. Serial sections
were stained for total PTEN (bottom pho-
tomicrographs) and phosphoPTEN
(upper photomicrographs); the reaction
color is reddish-brown. Separate sec-
tions were stained for PCNA to identify
replicating SMCs. The percentage of
PCNA-positive cells was determined per
condition, and the data are presented in
the graph as the meanSE. *P0.05,
different than PN /. C, Monoclonal
perlecan-specific antibody was used to
localize perlecan protein in aortas of
mouse E17.5 PN / embryos; the
reaction color is reddish-brown.
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Alternatively, or in addition to the effects of perlecan HS
chains and a hypothesis we favor, much of the growth
inhibitory signals could arise from perlecan core protein
interactions with cell surface receptors. Perlecan specifically
binds membrane-bound proteins, including dystroglycan and
integrins, which could be involved in cell signaling.41,42
Receptor-mediated perlecan-induced increases in PTEN ac-
tivity would block downstream of growth factor receptor and
integrin signals that would otherwise coordinately increase
cell proliferation. In addition to the effects on growth,
morpholino-mediated knockdown of endogenous PTEN also
reduced endogenous FRNK levels, an SMC-specific endog-
enous inhibitor of FAK activity.43 Along with direct antago-
nism of proliferative signals, increased PTEN activity could
also signal to transcription factors involved in FRNK mRNA
expression.27 Loss of SMC-perlecan interactions, as observed
in rapid SMC proliferative phases during vascular develop-
ment and after vascular injury, would release active growth
inhibitory signals and essentially tip the balance toward
proliferative signals. Identification of a perlecan receptor
capable of eliciting growth inhibitory signals and the phos-
phatase responsible for regulation of PTEN activity should
therefore provide further insights into how perlecan activates
PTEN to induce SMC growth arrest.
Surprisingly, little is known of transcriptional/posttransla-
tional signals associated with SMC-specific perlecan expres-
sion. The antiatherogenic factor apolipoprotein E increases
endothelial cell–derived perlecan protein synthesis/secretion
and sulfation of heparan sulfate chains contributing to
perlecan-induced SMC growth arrest44 and TGF-1 induces
fibroblast-specific perlecan expression.45 In contrast, athero-
genic factors, such as oxidized LDL, decrease perlecan core
protein synthesis/secretion and increase heparan sulfate deg-
radation via increased heparanase secretion. Whether these
factors have similar effects on SMC-derived perlecan has yet
to be determined. Clearly, selectively targeting perlecan,
PTEN, or factors modulating perlecan expression holds
promise for the development of antirestenotic and/or antiath-
erosclerotic therapies.
Despite major advances in vascular biology, mechanisms
regulating continual SMC replication during pathological
lesion formation remain unknown thus compounding the
challenge of successful clinical treatment. Defining endoge-
nous SMC growth-suppressive mechanisms in the mature
vessel wall could lead to a targeted molecular approach
focusing on such mechanisms to reduce lesion formation.
Based on the present study and our previous work, we
propose PTEN is less active in developing SMCs, thus
contributing to a highly proliferative growth phenotype. At
distinct developmental times, differentiating SMCs produce
increasing amounts of perlecan, which contribute to upregu-
lation of PTEN activity and subsequent loss of constitutive
proliferative signals, both associated with SMC quiescence.
Vascular injury, however, results in local perlecan proteoly-
sis, decreased PTEN activity, and increased proliferative
signaling events. In addition, SMC precursors recruited to the
site of injury pass through a series of developmental events
including low perlecan production and PTEN activity asso-
ciated with rapid growth. Our ongoing studies are addressing
several aspects of this overall proposal.
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